#KN522

Oncology Brothers

@oncbrothers.bsky.social

1 year ago

4. #KN522: current SoC PeriOp IO + neoAdj Chemo and then Adj IO for high risk TNBC.

- This remains the current standard of care. As of now, there are no specific markers available in clinical practice to predict IO benefit in these patients.

5/5

Oncology Brothers

@oncbrothers.bsky.social

1 year ago

#SABCS24 Day 1 Highlights #CommunityOnc:

1. @FDAOncology Reviews recent approvals: #Ribociclib & #Inavolisib

2. #PADMA: HR+ ET + CDK4/6i vs Chemo 1L

3. #DB06: HR+ TDXd

4. #KN522: biomarker analysis

#OncSky #CanSky @sabcs.bsky.social @drsarahsammons.bsky.social @dr-rshatsky.bsky.social

1/5

Elisabetta Bonzano MD, PhD

@elisabettabonzano.bsky.social

1 year ago

📌Immunotherapy for Early-Stage Triple-Negative Breast Cancer | New England Journal of Medicine
nejm.org/doi/full/10.10…
“Early-stage triple-negative breast cancer has an identity that is defined by what it needs, not what it lacks”
@oncoalert.bsky.social #OncoAlertAF #BreatCancer #Editorial #KN522

Oncology Brothers

@oncbrothers.bsky.social

1 year ago

< 2 weeks to #SABCS24, here is a📝 of🔑abstracts from #CommunityOncologists perspective.

- #EUROPA
- #EMBER3
- #SONIA
- #PADMA
- #TOUCH
- #DB012
- #OlympiA
- #KN522
- #REDUSE

#MedEd #bcsm #OncSky #breastcancer #MedSky @dr-rshatsky.bsky.social @drgattimays.bsky.social @hoperugo.bsky.social